126 related articles for article (PubMed ID: 16430653)
1. Distribution of neuropeptide Y-containing nerves in the neurogenic and non-neurogenic detrusor.
Haferkamp A; Freund T; Wagener N; Reitz A; Schurch B; Doersam J; Schumacher S; Bastian PJ; Buettner RJ; Mueller SC; Hohenfellner M
BJU Int; 2006 Feb; 97(2):393-9. PubMed ID: 16430653
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of neurogenic bladder dysfunction. III. Intrinsic detrusor innervation.
Haferkamp A; Dörsam J; Resnick NM; Yalla SV; Elbadawi A
J Urol; 2003 Feb; 169(2):555-62. PubMed ID: 12544306
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of connexin 43 in the overactive neurogenic detrusor.
Haferkamp A; Mundhenk J; Bastian PJ; Reitz A; Dörsam J; Pannek J; Schumacher S; Schurch B; Büttner R; Müller SC
Eur Urol; 2004 Dec; 46(6):799-805. PubMed ID: 15548450
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of neurogenic bladder dysfunction. II. Myogenic basis of detrusor hyperreflexia.
Haferkamp A; Dörsam J; Resnick NM; Yalla SV; Elbadawi A
J Urol; 2003 Feb; 169(2):547-54. PubMed ID: 12544305
[TBL] [Abstract][Full Text] [Related]
5. Structural basis of neurogenic bladder dysfunction. I. Methods of prospective ultrastructural study and overview of the findings.
Elbadawi A; Resnick NM; Dörsam J; Yalla SV; Haferkamp A
J Urol; 2003 Feb; 169(2):540-6. PubMed ID: 12544304
[TBL] [Abstract][Full Text] [Related]
6. P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin.
Brady CM; Apostolidis A; Yiangou Y; Baecker PA; Ford AP; Freeman A; Jacques TS; Fowler CJ; Anand P
Eur Urol; 2004 Aug; 46(2):247-53. PubMed ID: 15245821
[TBL] [Abstract][Full Text] [Related]
7. Adherens junctions of the human detrusor.
Wagener N; Reitz A; Pfitzenmaier J; Pannek J; Bastian PJ; Büttner R; Müller SC; Hohenfellner M; Haferkamp A
BJU Int; 2005 Oct; 96(6):843-7. PubMed ID: 16153214
[TBL] [Abstract][Full Text] [Related]
8. [Observation of neuropeptides in bladder after spinal cord injury in rats].
LI RZ; ZHOU MW; ZENG FS
Zhonghua Yi Xue Za Zhi; 2012 Apr; 92(15):1058-61. PubMed ID: 22781650
[TBL] [Abstract][Full Text] [Related]
9. Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study.
Madersbacher H; Mürtz G; Alloussi S; Domurath B; Henne T; Körner I; Niedeggen A; Nounla J; Pannek J; Schulte-Baukloh H; Schultz-Lampel D; Bock P; Strugala G
BJU Int; 2009 Mar; 103(6):776-81. PubMed ID: 19007380
[TBL] [Abstract][Full Text] [Related]
10. [Video-urodynamic studies on 1800 patients with neurogenic bladder].
JU YH; LIAO LM; LI D; FU G; LIANG WL; XIONG ZS; WU J; SHI WB; HAN CS
Zhonghua Wai Ke Za Zhi; 2008 Oct; 46(20):1525-8. PubMed ID: 19094643
[TBL] [Abstract][Full Text] [Related]
11. Neurogenic detrusor overactivity: comparison between complete and incomplete spinal cord injury patients.
Moslavac S; Dzidic I; Kejla Z
Neurourol Urodyn; 2008; 27(6):504-6. PubMed ID: 18508334
[TBL] [Abstract][Full Text] [Related]
12. Neuropeptide Y- and vasoactive intestinal polypeptide-containing nerves in the intrinsic external urethral sphincter in the areflexic bladder compared to detrusor-sphincter dyssynergia in patients with spinal cord injury.
Milner P; Crowe R; Burnstock G; Light JK
J Urol; 1987 Oct; 138(4):888-92. PubMed ID: 3656550
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury.
Patki PS; Hamid R; Arumugam K; Shah PJ; Craggs M
BJU Int; 2006 Jul; 98(1):77-82. PubMed ID: 16831148
[TBL] [Abstract][Full Text] [Related]
14. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
Giannantoni A; Mearini E; Del Zingaro M; Porena M
Eur Urol; 2009 Mar; 55(3):705-11. PubMed ID: 18814955
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction.
Pannek J; Göcking K; Bersch U
BJU Int; 2009 Nov; 104(9):1246-50. PubMed ID: 19426192
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
Kennelly MJ; Lemack GE; Foote JE; Trop CS
Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
[TBL] [Abstract][Full Text] [Related]
17. Patients with lower motor spinal cord lesion: a decrease of vasoactive intestinal polypeptide, calcitonin gene-related peptide and substance P, but not neuropeptide Y and somatostatin-immunoreactive nerves in the detrusor muscle of the bladder.
Crowe R; Moss HE; Chapple CR; Light JK; Burnstock G
J Urol; 1991 Mar; 145(3):600-4. PubMed ID: 1705295
[TBL] [Abstract][Full Text] [Related]
18. Persistence of the synaptosomal-associated protein-25 cleavage product after intradetrusor botulinum toxin A injections in patients with myelomeningocele showing an inadequate response to treatment.
Schulte-Baukloh H; Zurawski TH; Knispel HH; Miller K; Haferkamp A; Dolly JO
BJU Int; 2007 Nov; 100(5):1075-80. PubMed ID: 17784887
[TBL] [Abstract][Full Text] [Related]
19. Treatment of neurogenic detrusor overactivity in spinal cord injured patients by conditional electrical stimulation.
Hansen J; Media S; Nøhr M; Biering-Sørensen F; Sinkjaer T; Rijkhoff NJ
J Urol; 2005 Jun; 173(6):2035-9. PubMed ID: 15879820
[TBL] [Abstract][Full Text] [Related]
20. Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction.
Akbar M; Abel R; Seyler TM; Bedke J; Haferkamp A; Gerner HJ; Möhring K
BJU Int; 2007 Sep; 100(3):639-45. PubMed ID: 17532858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
